CVS Health enters its May 6 earnings call in a notably better place than it left the last few months — up 15.5% over the past month and shedding short positions at pace, yet options traders are quietly loading up on hedges ahead of the print.
The short-covering story is the cleanest narrative in the data. Short interest has fallen 20% over the past month to just 1.25% of the free float, down from a peak near 1.6% in late March. The pace of unwinding accelerated this week — shorts dropped another 7% in the last five trading days alone, reaching the lowest level in the 30-day window. Borrow costs remain modest at 0.51%, though that figure is up 30% on the week, suggesting a small uptick in demand even as the gross position shrinks. Availability is extremely loose, well above 1,000%, meaning there is no squeeze pressure whatsoever in the lending market. This is a stock where shorts are leaving, not being forced out.
Options positioning tells a more cautious tale. The put/call ratio climbed to 0.79, running about 1.5 standard deviations above its 20-day average of 0.70 — the most defensive read since early March. That gap matters because the stock has rallied hard into the print; investors appear to be using calls to ride the momentum while layering on put protection ahead of May 6. The 52-week PCR range runs from 0.61 to 0.99, so 0.79 is elevated but not extreme — cautious, rather than panicked.
The Street is modestly constructive. Multiple analysts carry Outperform or Overweight ratings with targets in the $94–$101 range. Baird raised its target to $94 earlier this month, keeping an Outperform. Piper Sandler trimmed slightly to $99 but held Overweight. The overall consensus sits at Hold with three named holds, though the direction of the most recent moves is upward. The stock at $80.98 is now trading at roughly a 10.8x P/E and 9.1x EV/EBITDA — both multiples have expanded meaningfully over 30 days as the price recovered. The bull case points to pharmacy script share growth and Health Services revenue running well ahead of expectations; bears flag weak EPS trajectory, declining claims volumes, and regulatory pressure on the insurance side.
The institutional ownership picture is broadly stable. BlackRock, Vanguard, and Capital Research each hold around 8–9% of shares. T. Rowe Price added nearly 3 million shares in Q1 — the most notable incremental move among major holders. Wellington Management also built a meaningful position. On the insider side, a cluster of executives including CEO John Joyner sold shares on April 1 at around $72.49 — at a price well below where the stock now trades. The sells were small in absolute terms and the highest trade significance score was 1 out of 10, suggesting routine programmatic activity rather than conviction selling.
Earnings history adds a useful reference point. The last two confirmed prints both produced modest positive 1-day moves — the February 2026 result moved the stock +1.6% on the day and +3.2% over the subsequent week. The December 2025 print was stronger at +3.2% on the day. The one exception in recent history was a modest -0.65% dip on the Q3 result. The pattern is of contained reactions with a slight bullish skew, rather than the large moves the stock saw in 2023–2024 during its extended drawdown.
What to watch on May 6: the debate between the improving retail pharmacy metrics and the lingering pressure on the insurance segment's medical loss ratio, and whether management's commentary on FY26 EPS trajectory is enough to close the gap between the current price and analyst targets sitting 15–20% higher.
See the live data behind this article on ORTEX.
Open CVS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
